Wockhardt share price jumps over 19% after US FDA accepts new drug application for Zaynich
Wockhardt, the pharmaceutical and biotechnology major, saw its shares soar sharply in Monday’s intraday session, December 01, surging 19.3% to hit the day’s high of ₹1,473 apiece. The sharp reversal in the stock from recent weakness was triggered after the company announced regulatory approval for its antibiotic drug Zaynich for bacterial infections.
The company, in its regulatory filing today, informed that the United States Food and Drug Administration (US FDA) has formally accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich.
The application was originally filed on September 30, 2025, and its acceptance marks a transformative moment—not only for Wockhardt, but also for the entire Indian…
